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will exceed the cumulative cessation cost in the 11th year and it will be 2.5 times 
in the 20th year; the cumulative medical cost plus productivity saving will exceed 
the cumulative cessation cost in the 7th year and it will be 3.4 times in the 20th 
year. ConClusions: Considering the attractive ROI results, it’s recommended that 
SC medicines should be covered in the SC intervention.
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objeCtives: To assess epinephrine auto-injector (EAI) availability and use for ana-
phylactic events in US schools during the 2013-2014 school year. Methods: This 
exploratory, cross-sectional, web-based survey analyzed anaphylactic events in eli-
gible schools participating in the Mylan-sponsored EpiPen4Schools® program, an 
ongoing initiative providing free EAIs and training to schools nationwide. Results: 
Survey participants consisted of 6019 of the > 40,000 schools in the EpiPen4Schools 
program. A total of 919 anaphylactic events were reported in 11% of schools (607/5683). 
Importantly, 22% of anaphylactic events (n= 187) occurred in individuals with no 
known allergies; most events (89%, 757/852) occurred in students. Of the 851 events 
with treatment information, 75% of individuals (n= 636) were administered epineph-
rine via an EAI, 49% (n= 310) of whom used the schools’ stock EAI provided through 
the EpiPen4Schools program (despite known prior allergies in 69% of anaphylactic 
cases). Of note was the disparity between the number of qualifying schools in the 
EpiPen4Schools program, nationwide, with Illinois having the highest (n= 2282) and 
District of Columbia the lowest (n= 4) number of participating schools. ConClusions: 
One in 10 schools participating in the survey reported ≥ 1 anaphylactic event during 
the 2013-2014 school year. Of those individuals treated with EAIs, nearly half used 
their school’s stock EAI, provided through the EpiPen4Schools program, suggesting 
the value of stocking EAIs for student/staff safety and potential cost savings. Studies 
on the cost of inpatient care for anaphylaxis indicate approximately $4700 per event. 
Furthermore, data suggest significantly higher treatment costs and poorer outcomes 
when treatment with an EAI is delayed. The prevalence of anaphylaxis continues to 
increase, as do the costs associated with receiving treatment and delaying or failing 
to receive treatment; removing barriers to access and increasing availability of treat-
ment is an important public health goal.
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objeCtives: The study aimed to evaluate the level of disease state knowledge among 
tuberculosis patients. Methods: A questionnaire based cross-sectional study was car-
ried out among patients with TB in Fatima Jinnah chest hospital Quetta. Data was col-
lected by a pre-tested structured questionnaire that contain twenty two (22) regarding 
information related to TB (including etiology, symptoms, transmission, diagnosis and 
treatment). The descriptive statistics was used to present the data. Inferential statistics 
was used to the evaluation relationship among study variables. All analyses were per-
formed using SPSS 20.0. Results: Majority (60.0%) of the study patients were female 
and belong to age group of 22 to 31 years (24.28%). Majority (41.4%) of the respondents 
were illiterate and had received religious education(31.4%). The mean knowledge score 
was 11.23 ± 3.6 which is categorized as poor knowledge and posters/broachers and 
other printed material was reported as major source of information. No demographic 
characteristic was influencing the mean knowledge scores. ConClusions: The study 
concluded that the TB patients had poor disease state knowledge. Efforts should be 
made educate the patients regardless to the demographic characteristics, so that better 
disease control and further spread of infection would be prevented.
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objeCtives: The presence of adverse events (AEs) associated with topical rosacea 
agents may lead to a lack of treatment adherence. Previous studies have reported 
low adherence rates among treated rosacea patients. This study describes the rate 
of treatment changes due to AEs and associated healthcare costs among rosacea 
patients receiving a topical therapy. Methods: Patients diagnosed with rosacea 
(ICD-9-CM: 695.3) who are newly initiating treatment with topical metronidazole, 
azelaic acid, sodium sulfacetamide/sulfur, benzoyl peroxide between 1/2009 and 
10/2013 were identified from MarketScan databases. Patients were required to 
be ≥ 30 years old, continuously eligible with medical and pharmacy benefits ≥ 12 
months pre- and ≥ 3 months post-treatment and without evidence of oral antibiotic 
or rosacea conjunctivitis during the study period. An AE was defined as a treatment 
switch within 2 weeks or medical claim with an AE diagnosis code. Persistence was 
defined as continuous refill of the index drug/formulation within 1.5 times the days’ 
supply of the prior prescription. Rate of AEs, treatment patterns, and healthcare 
costs were evaluated in the post-index period. Results: This analysis included 
49,351 patients. The mean age was 54 years and 25.5% were male. Metronidazole 
(72.7%) was the most common treatment and the predominant formulation was gel 
nificant differences were found in adherence across age groups (p= 0.34), genders 
(p= 0.43), or races (p= 0.62). ConClusions: Adherence to COPD maintenance medi-
cations was low among Medicare beneficiaries with COPD.
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objeCtives: To measure the extent to which closing the coverage gap will affect drug 
utilization, access, and OOP spending among seniors with chronic diseases, includ-
ing respiratory diseases (asthma or COPD), hypertension, hyperlipidemia, psychosis, 
depression, and diabetes. Methods: A difference-in-difference-in-difference (DDD) 
analysis from 2008 to 2012 was used. Results: The Medical Expenditure Panel Survey 
data files from 2008 to 2012 imply that closing the coverage gap had no significant 
impact on the disparities in annual drug expenditures, OOP spending, and total num-
ber of prescriptions between minorities and whites. However, it significantly increased 
the disparity in access to prescriptions between minorities and whites by 3.8 percent. 
When teasing out the effect by race, the results show that closing the coverage gap 
had no significant impact on the disparities in OOP spending and total number of pre-
scriptions between African-Americans and whites, while it significantly increased the 
disparity in access to prescriptions for by 7.3 percent, and significantly decreased the 
disparity in annual drug expenditures by $1,162. Regarding Hispanics, it significantly 
increased the disparities in OOP spending and total number of prescription drugs by 
$325 and 8 prescriptions, respectively. However, it had no significant impact on the 
disparities in annual drug expenditures and access to prescriptions. ConClusions: 
The findings of this study demonstrate that the benefits of closing the coverage gap 
are disproportionately distributed among different racial groups. Closing the coverage 
gap decreased disparities in annual drug expenditures, OOP spending, and access to 
prescription drugs for African-American compared to white, while It increased dis-
parities in annual drug expenditures, OOP spending, and total number of prescription 
for Hispanics compared to whites.
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objeCtives: Decisions regarding formulary generosity of exchange-based plans have 
undoubtedly affected uptake of specific therapies at a time of guaranteed-issue cover-
age and out-of-pocket maximums. This study examined formulary decisions made by 
managed care organizations for their exchange-based plans, and assessed the impact 
of these decisions on brand prescribing for asthma, bipolar disorder, and multiple 
sclerosis, to discern differences between indications. Methods: Surveys of 120 MCO 
pharmacy and medical directors, and 270 pulmonologists, psychiatrists, neurologists, 
and primary care physicians were conducted in 2014 and 2015 to determine formulary 
coverage on exchange-based plans, and the impact of this coverage on brand prescrib-
ing to patients covered by such plans. Results: Some 41% of surveyed MCOs reported 
the formularies of their exchange-based plan and largest commercial plan to be dis-
tinct; the exchange-based plans of 52% of these respondents covered fewer brands 
overall. Furthermore, increased tier 3+ (non-preferred) coverage and/or exclusion of 
some brands in/from their exchange-based plans versus their largest commercial plans 
were noted by an average of 8%, 10%, and 0% of MCOs for asthma, bipolar disorder, 
and multiple sclerosis drugs, respectively. In response, surveyed physicians reported 
decreased prescribing of specific drugs, particularly those competing versus generics, 
that were subject to less favorable/complete lack in exchange-based coverage versus 
traditional commercial coverage. The greatest impact of less favorable exchange-based 
plan coverage on uptake was on bipolar disorder, where, for example Seroquel XR 
was prescribed to 8% of exchange-based plan patients versus 5% of commercial plan 
patients. ConClusions: Less-generous reimbursement on exchange-based plans is 
evident, demonstrating desires by MCOs to limit costs on these plans. Consequently, 
there is increased prescribing of generics and preferred brands when available over 
higher-cost agents. Therapy areas with a number of cheaper options will be most 
affected, while specialty therapy areas will remain largely immune to this trend.
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objeCtives: Knowing the return-on-investment of smoking cessation (SC) is critical 
for policy makers to understand its economic benefit and implement effective SC 
intervention. The study sought to assess the return-on-investment (ROI) of smoking 
cessation in Guangdong, China and inform its economic benefit to policy mak-
ers. Methods: A decision tree model about ROI of SC benefit comparison was 
developed and adapted, which compared the costs, benefits and outcomes of 2 
SC benefit scenarios over 20-year time frame. The main difference between the 2 
scenarios was whether SC medicines were covered or not. Key inputs were obtained 
from available public sources, including smoking population, potential medical 
costs and savings along with productivity improvement, participants’ expected 
quit rates and relapses, etc. Results: If SC medicines are covered, the number 
of attempts and successes will increase 11 million and 1.3 million respectively 
in 20 years in Guangdong; the annual medical cost saving will exceed the annual 
cessation cost in the 6th year and it will be 7.7 times in the 20th year; the annual 
medial cost plus productivity saving will exceed the annual cessation cost in the 
4th year and it will be 9.5 times in the 20th year; the cumulative medical cost saving 
